Dovitinib in association with fulvestrant showed promising clinical efficacy to ER + or HER2 + breast cancer in postmenopausal women in a phase II clinical setting (NCT01528345); however, the trial was discontinued in response to the poor enrollment of FGF-expressing patients [136]. This evidence concerns the gene ERBB2 and breast cancer.